Clinical trials
Allogeneic Stem Cell Transplantation clinical trials
Below are recruiting allogeneic stem cell transplantation clinical trials, each written for real people, not researchers. We’re tracking 386 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05152394RecruitingPhase 1
Testing cord stem cell exosome treatment for Parkinson’s safety
This Phase 1 study tests whether a treatment made from donated umbilical cord “exosomes” is safe in people with Parkinson’s disease. It mainly looks at side effects and safety, and could help guide future treatments if it proves tolerable.
St John'sAges Any age - NCT05158101RecruitingPhase 1
Nasal stem cell exosome treatment safety for stroke
This early-stage study (Phase 1) tests whether a tiny dose given through the nose is safe for people who have had a stroke. It uses exosomes made from adult umbilical cord stem cells, mainly to look for side effects and dosing safety.
St John'sAges Any age - NCT06143527RecruitingPhase 1
Stem cell safety trial for PCOS
This early-phase trial tests whether stem cells from donated umbilical cords are safe for people with PCOS (polycystic ovary syndrome). If you qualify, you would receive an infusion of these cells and be monitored for safety.
St John'sAges 18 years+ - NCT06321289RecruitingPhase 1/Phase 2
Donor T cell therapy for B-cell lymphoma
This trial tests a new type of therapy where specially designed donor T cells target your lymphoma. It's for people with certain B-cell non-Hodgkin lymphomas that have not responded to or returned after standard treatments. You might join if you meet the health and disease criteria listed below.
Beijing, Beijing MunicipalityAges 18–75 - NCT04211259RecruitingEarly Phase 1
Loratadine to reduce bone pain during stem cell collection
This early trial studies whether loratadine (an allergy medicine) can reduce bone pain caused by G-CSF, which is used to help your body collect stem cells. If you have multiple myeloma and are preparing for stem cell mobilization, this may make treatment-related bone pain more tolerable.
New Brunswick, New JerseyAges 18 years+ - NCT04517656Recruiting
Testing blood markers after a bone marrow donor transplant
This trial checks how certain blood “biomarkers” change after you receive donor stem cells to rebuild your blood and immune system. The goal is to learn whether these markers can better predict your immune recovery after transplant.
Saint-EtienneAges 18 years+ - NCT03081910RecruitingPhase 1
CAR T cells made from your own cells to treat CD5 tumors
This early-phase trial tests a type of immune-cell therapy (CAR T cells) made using T cells with a CD5-targeting “zipper” to treat certain relapsed T-cell cancers. The goal is to see if the treatment can help shrink or clear the cancer, especially enough to move toward a stem cell transplant plan.
Houston, TexasAges Up to 75 years - NCT05391490RecruitingPhase 1
Testing donated immune cells for advanced CD19 blood cancers
This early-phase trial tests donated (allogeneic) immune cells engineered to recognize CD19, a target found on many B-cell cancers. It’s designed for people whose CD19+ cancer has come back or didn’t respond after several previous treatments, aiming to shrink tumors and control disease.
LondonAges 16–65 - NCT06765564Recruiting
Study of stem cell therapy for amyotrophic lateral sclerosis (ALS) progression
This study tests whether a new treatment using special motor neuron cells made from stem cells (iPSCs) can help people with ALS. The cells will be transplanted into the spinal cord to try to slow the disease and improve function.
Shanghai, Shanghai MunicipalityAges 18–60 - NCT03173937RecruitingPhase 1/Phase 2
Cord blood transplant for severe aplastic anemia or MDS
This trial tests a special type of cord blood transplant using lab-grown stem cells to help the new blood-forming cells “take” sooner. It’s for people with severe aplastic anemia or certain MDS cases who have not responded well to standard immune-suppressing treatments.
Bethesda, MarylandAges 4–75 - NCT06008808RecruitingPhase 1
Ruxolitinib and abatacept to prevent GVHD after haplo transplant
This trial tests whether a drug called ruxolitinib, with or without another drug called abatacept, can prevent graft-versus-host disease and cytokine release syndrome after a half-matched stem cell transplant from a family donor. It's for people with certain blood cancers who are getting this type of transplant.
St Louis, MissouriAges 18 years+ - NCT07366658RecruitingPhase 1
Experimental therapy for neuroendocrine tumors that did not respond to treatment
This trial tests an experimental therapy (NEUK203-13) for people with neuroendocrine tumors, including small cell lung cancer, that have not responded to or stopped responding to standard treatments. It aims to see if the drug is safe and to look for early signs that it might shrink tumors, especially in people whose tumors have a specific marker called DLL3.
BeijingAges 18–75 - NCT05400603RecruitingPhase 1
Immunotherapy trial for relapsed neuroblastoma or osteosarcoma
This Phase 1 study tests lab-made donor immune cells (gamma delta T cells) plus chemotherapy to treat neuroblastoma or osteosarcoma that has come back or hasn’t responded to standard treatment. It’s designed to find a safe way to give this treatment and to see how well it might work.
Atlanta, GeorgiaAges 1 year+ - NCT06442761RecruitingPhase 1
Collecting stem cells for gene therapy in sickle cell disease
This study tests a new drug called motixafortide to help collect your own blood stem cells for future gene therapy. It is for adults with severe sickle cell disease who are willing to donate their stem cells and meet certain health requirements.
Birmingham, AlabamaAges 18 years+ - NCT04959903RecruitingPhase 1/Phase 2
SMART101 after T-cell–depleted bone marrow transplant for blood cancers
This early-phase study tests SMART101 given after a T-cell–depleted (T-cell removed) donor bone marrow transplant. It aims to see if the treatment is safe and can help control certain high-risk blood cancers in children and adults.
New York, New YorkAges Any age - NCT04024761RecruitingPhase 1
NK cell therapy for leukemia relapse after transplant
This Phase 1 study tests whether an infusion of special immune cells (NK cells) from a donor can help control leukemia or related blood cancers that come back or do not fully go away after a stem cell transplant. It also uses short chemotherapy to “make space” for the NK cells to work, and IL-2 to help them function.
Boston, MassachusettsAges 12 years+ - NCT06119256RecruitingPhase 1
TCR-T cells for EBV after stem cell transplant
This trial tests a new treatment using specially trained immune cells (TCR-T cells) to fight Epstein-Barr virus (EBV) infections that can occur after a stem cell transplant for blood cancer. It may help control the virus and prevent complications.
Beijing, Beijing MunicipalityAges 14–75 - NCT06647979RecruitingPhase 1
Gene editing for severe sickle cell or thalassemia
This trial tests a new gene therapy that edits your own blood stem cells to help them make more fetal hemoglobin, which can prevent sickling and reduce the need for transfusions. It is for people with severe sickle cell disease or beta thalassemia who do not have a matched sibling donor.
Boston, MassachusettsAges 13–40 - NCT06575426RecruitingPhase 1/Phase 2
Testing pig pancreas cells for type 1 diabetes
This trial tests a treatment made from pig pancreas cells (OPF-310) to see if it's safe and can help people with unstable type 1 diabetes. The cells are meant to replace the insulin-producing cells your body has lost, potentially reducing dangerous low blood sugar events.
Chicago, IllinoisAges 35–65 - NCT05864170RecruitingEarly Phase 1
Tested injection for severe transfusion-dependent thalassemia
This early-stage study tests the safety and possible benefits of an injection called HGI-001 for people with severe transfusion-dependent beta thalassemia. It may help by preparing you for stem cell transplant, but you must meet several health and lab criteria and be able to return often for follow-up tests.
Shenzhen, GuangdongAges 18–35 - NCT05851105RecruitingEarly Phase 1
Study drug for severe alpha thalassemia in people needing regular transfusions
This early-phase trial studies HGI-002 to see if it’s safe and can help people with severe alpha thalassemia who need frequent blood transfusions. It also requires planning for a special treatment approach that includes busulfan pre-treatment and stem cell transplantation.
Nanning, GuangxiAges 12–35 - NCT06465550RecruitingPhase 1
Gene therapy for beta-thalassemia in children and teens
This trial tests a new gene therapy (BD211) for children and teens with severe beta-thalassemia who need regular blood transfusions. The treatment uses your own blood stem cells, modified with a working gene, to help your body make healthy red blood cells and reduce the need for transfusions.
Guangzhou, GuandongAges 3–35 - NCT05773729Recruiting
Gene-modified own stem cell treatment for transfusion-dependent thalassemia
This trial tests a one-time treatment that uses your own (autologous) stem cells that have been changed by gene methods, then returned to you to help manage transfusion-dependent beta-thalassemia. It aims to check safety and whether it can reduce the need for frequent blood transfusions or improve blood health.
ShanghaiAges 3–18 - NCT05776173Recruiting
Gene-modified stem cell treatment for transfusion-dependent thalassemia
This trial tests whether giving you your own (autologous) gene-modified blood stem cells can improve transfusion-dependent beta-thalassemia and its safety. It may help people who do not have a fully matched donor and need an alternative approach to care.
ShanghaiAges 6–35
Hear when a new Allogeneic Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for allogeneic stem cell transplantation?
- Yes. Clin2 currently lists 386 recruiting allogeneic stem cell transplantation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a allogeneic stem cell transplantation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a allogeneic stem cell transplantation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Allogeneic Hematopoietic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Hematopoietic Stem Cell Transplantation
- Stem Cell Transplantation
- Hematopoetic Stem Cell Transplantation
- Haploidentical Hematopoietic Stem Cell Transplantation
- Autologous Hematopoietic Stem Cell Transplantation
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.